Thus, we conducted this meta-analysis of randomized controlled trials (RCTs) to thoroughly characterize the effects of SGLT2 inhibitors on eGFR and albuminuria compared with placebo or other antidiabetic treatments in patients with type 2 diabetes. Here, SLC5A2 is linked to type 2 diabetes mellitus.